BR9610308A - Peptídios de fator anti-secretório reguladores de alterações de permeabilidade patológica - Google Patents
Peptídios de fator anti-secretório reguladores de alterações de permeabilidade patológicaInfo
- Publication number
- BR9610308A BR9610308A BR9610308-6A BR9610308A BR9610308A BR 9610308 A BR9610308 A BR 9610308A BR 9610308 A BR9610308 A BR 9610308A BR 9610308 A BR9610308 A BR 9610308A
- Authority
- BR
- Brazil
- Prior art keywords
- fragments
- counterparts
- protein
- secretory factor
- raf
- Prior art date
Links
- 230000001575 pathological effect Effects 0.000 title abstract 3
- 108010038288 antisecretory factor Proteins 0.000 title abstract 2
- 230000035699 permeability Effects 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003793 antidiarrheal agent Substances 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010030113 Oedema Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 229940125714 antidiarrheal agent Drugs 0.000 abstract 1
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
Abstract
Patente de Invenção: <B>"PEPTìDIOS DE FATOR ANTI-SECRETóRIO REGULADORES DE ALTERAçõES DE PERMEABILIDADE PATOLóGICA"<D>. Um nova proteína recombinante denominada Fator Anti-Secretório (rAF) e os seus homólogos e fragmentos de peptídeos são descritos. A proteína e os seus homólogos e fragmentos são utéis para a normalização de transporte fluido patológico e/ou reações inflamatórias em animais, incluindo seres humanos. Os anticorpos contra AF ou os seus homólogos ou fragmentos são descritos. Os ácidos nucléicos de codificação para a proteína ou dos seus homólogos ou fragmentos também são descritos , bem como os vetores e hospedeiros compreendendo os ácidos nucléicos. O rAF e ou seus homólogos ou fragmentos poderiam ser usados para detecção imunológica, como complemento alimentar no crescimento de animais e como agentes antidiarréicos e drogas contra doenças envolvendo edema, desidratação e/ou inflamação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502936A SE508609C2 (sv) | 1995-08-24 | 1995-08-24 | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
| PCT/SE1996/001049 WO1997008202A1 (en) | 1995-08-24 | 1996-08-23 | Antisecretory factor peptides regulating pathological permeability changes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9610308A true BR9610308A (pt) | 1999-12-21 |
Family
ID=20399269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9610308-6A BR9610308A (pt) | 1995-08-24 | 1996-08-23 | Peptídios de fator anti-secretório reguladores de alterações de permeabilidade patológica |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6344440B1 (pt) |
| EP (1) | EP0851876B1 (pt) |
| JP (2) | JP4040679B2 (pt) |
| KR (1) | KR100552947B1 (pt) |
| CN (1) | CN1171902C (pt) |
| AT (1) | ATE270305T1 (pt) |
| AU (1) | AU702589B2 (pt) |
| BG (1) | BG63209B1 (pt) |
| BR (1) | BR9610308A (pt) |
| CA (1) | CA2230111C (pt) |
| CZ (1) | CZ295444B6 (pt) |
| DE (2) | DE69632828T2 (pt) |
| DK (1) | DK0851876T3 (pt) |
| EA (1) | EA001201B1 (pt) |
| EE (1) | EE04501B1 (pt) |
| ES (1) | ES2118683T3 (pt) |
| HK (1) | HK1018468A1 (pt) |
| HU (1) | HU224971B1 (pt) |
| IL (1) | IL123404A (pt) |
| NO (1) | NO320560B1 (pt) |
| NZ (2) | NZ316647A (pt) |
| PL (1) | PL188530B1 (pt) |
| PT (1) | PT851876E (pt) |
| RO (1) | RO120197B1 (pt) |
| SE (1) | SE508609C2 (pt) |
| SI (1) | SI0851876T1 (pt) |
| SK (1) | SK23698A3 (pt) |
| TR (1) | TR199800304T1 (pt) |
| WO (1) | WO1997008202A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE508609C2 (sv) * | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
| SE9604251L (sv) * | 1996-11-20 | 1997-12-22 | Svenska Lantmaennen Riksfoerbu | Födoämne som vid förtäring inducerar antisekretoriska proteiner |
| SE513496C2 (sv) | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
| CA2340721A1 (en) * | 1999-06-21 | 2001-01-25 | George Tuszynski | Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| PL2037950T3 (pl) | 2006-04-27 | 2014-09-30 | Lantmaennen As Faktor Ab | Dodatkowe zastosowania medyczne białka antysekrecyjnego |
| DK2468292T3 (da) * | 2006-04-27 | 2020-03-23 | Lantmaennen Medical Ab | Nyt peptid med antisekretorisk aktivitet |
| DK2363140T3 (en) * | 2006-04-27 | 2017-03-06 | Lantmännen As-Faktor Ab | ANTI-SECRETORIC PROTEIN TO USE IN THE TREATMENT OF COMPARTMENT SYNDROME |
| US8901083B2 (en) | 2008-11-25 | 2014-12-02 | Temple University | Administration of angiocidin for the treatment of leukemia |
| EP3769778A1 (en) | 2009-02-11 | 2021-01-27 | Lantmännen Medical AB | Use of antisecretory factors (af) for optimizing cellular uptake |
| CA2992057C (en) | 2015-07-10 | 2021-07-20 | Lantmannen As-Faktor Ab | Process for producing egg yolk with high content of af-16 |
| JP6999638B2 (ja) * | 2016-07-18 | 2022-01-18 | ラントメネン・メディカル・アーベー | 抗分泌性因子１７ |
| CA3103164A1 (en) | 2018-06-28 | 2020-01-02 | Lantmannen Medical Ab | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure |
| WO2020065091A1 (en) | 2018-09-28 | 2020-04-02 | Lantmännen Functional Foods Ab | A consumable product comprising malted wheat |
| EP3855934A2 (en) | 2018-09-28 | 2021-08-04 | Lantmännen Functional Foods AB | A consumable product comprising malted dehulled oat |
| CA3173436A1 (en) | 2020-03-26 | 2021-09-30 | Leif Goransson | A consumable product comprising malted cereals for promoting recovery at physical activity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE508609C2 (sv) * | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
-
1995
- 1995-08-24 SE SE9502936A patent/SE508609C2/sv not_active IP Right Cessation
-
1996
- 1996-08-23 SI SI9630013T patent/SI0851876T1/xx unknown
- 1996-08-23 RO RO98-00364A patent/RO120197B1/ro unknown
- 1996-08-23 WO PCT/SE1996/001049 patent/WO1997008202A1/en active IP Right Grant
- 1996-08-23 DK DK96929619T patent/DK0851876T3/da active
- 1996-08-23 AU AU68932/96A patent/AU702589B2/en not_active Expired
- 1996-08-23 TR TR1998/00304T patent/TR199800304T1/xx unknown
- 1996-08-23 PT PT96929619T patent/PT851876E/pt unknown
- 1996-08-23 PL PL96325114A patent/PL188530B1/pl unknown
- 1996-08-23 IL IL12340496A patent/IL123404A/xx not_active IP Right Cessation
- 1996-08-23 EA EA199800221A patent/EA001201B1/ru not_active IP Right Cessation
- 1996-08-23 CA CA2230111A patent/CA2230111C/en not_active Expired - Lifetime
- 1996-08-23 EE EE9800055A patent/EE04501B1/xx not_active IP Right Cessation
- 1996-08-23 JP JP51018597A patent/JP4040679B2/ja not_active Expired - Lifetime
- 1996-08-23 DE DE69632828T patent/DE69632828T2/de not_active Expired - Lifetime
- 1996-08-23 ES ES96929619T patent/ES2118683T3/es not_active Expired - Lifetime
- 1996-08-23 US US09/029,333 patent/US6344440B1/en not_active Expired - Lifetime
- 1996-08-23 SK SK236-98A patent/SK23698A3/sk unknown
- 1996-08-23 CZ CZ1998520A patent/CZ295444B6/cs not_active IP Right Cessation
- 1996-08-23 DE DE0851876T patent/DE851876T1/de active Pending
- 1996-08-23 CN CNB961973005A patent/CN1171902C/zh not_active Expired - Lifetime
- 1996-08-23 EP EP96929619A patent/EP0851876B1/en not_active Expired - Lifetime
- 1996-08-23 KR KR1019980701343A patent/KR100552947B1/ko not_active IP Right Cessation
- 1996-08-23 HU HU9900137A patent/HU224971B1/hu unknown
- 1996-08-23 AT AT96929619T patent/ATE270305T1/de active
- 1996-08-23 NZ NZ316647A patent/NZ316647A/en not_active IP Right Cessation
- 1996-08-23 BR BR9610308-6A patent/BR9610308A/pt not_active IP Right Cessation
-
1998
- 1998-02-23 NO NO19980743A patent/NO320560B1/no not_active IP Right Cessation
- 1998-02-24 BG BG102280A patent/BG63209B1/bg unknown
-
1999
- 1999-08-17 HK HK99103574A patent/HK1018468A1/xx not_active IP Right Cessation
- 1999-08-20 NZ NZ337380A patent/NZ337380A/en not_active IP Right Cessation
-
2001
- 2001-11-26 US US09/991,792 patent/US20020099016A1/en not_active Abandoned
-
2007
- 2007-07-25 JP JP2007193054A patent/JP2008043331A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9610308A (pt) | Peptídios de fator anti-secretório reguladores de alterações de permeabilidade patológica | |
| Porter | Chemical structure of γ-globulin and antibodies | |
| Hanes et al. | Identification and partial characterization of the major royal jelly protein of the honey bee (Apis mellifera L.) | |
| HUP0003533A2 (hu) | Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk | |
| DE69333802D1 (de) | Äusseres membranprotein von haemophilus | |
| Takagi et al. | Complete amino acid sequence of human α1-microglobulin | |
| Tsuda | Purification and characterization of a lectin from the mushroom, Flammulina veltipes | |
| Nakai et al. | Amino acid sequence of toxin A from the venom of the Indian cobra (Naja naja) | |
| Radwan et al. | Toxinological studies on the nematocyst venom of Chrysaora achlyos | |
| Wynn | Solubilization of insoluble collagens by rat liver lysosomes | |
| DE69230881D1 (de) | Corticotropinauslösefaktor-bindendes protein | |
| Moroz-Perlmutter et al. | Biochemical and antigenic properties of a purified neurotoxin of Vipera palestinae venom | |
| Knyszynski et al. | Increase of haptoglobin concentration in mouse serum by endotoxin and by a serum factor | |
| TOSA et al. | Puritication and Identification of a Serum Protein Increased by Anthelmintic Drugs for Dirofilaria immitis in Dogs | |
| Nakagawa et al. | Complement component C3-derived neutrophil chemotactic factors purified from exudate of rat carrageenin-induced inflammation | |
| ATE512162T1 (de) | Antikörper gegen das p51 protein | |
| Levenbook et al. | Ubiquitin in the blowfly Calliphora vicina: Partial characterization, titers during the life cycle and relation to calliphorin breakdown | |
| Black et al. | Isolation, partial characterization, and localization of the A and B proteins from the tubular accessory gland of male Tenebrio molitor | |
| Roy et al. | Electrophoretic detection of myeloperoxidase, protease, lactoferrin and lysozyme in buffalo polymorphonuclear granular acid extracts | |
| Absar et al. | Purification, characterization and N-terminal sequences alignment of a mannose specific protein purified from Potca fish, Tetraodon patoca | |
| Hoshi et al. | Isolation of Bovine β₂-Microglobulin and its Determination by Enzyme Liked Immunosorbent Assay | |
| Hoe et al. | Preliminary Study on Saliva from Diabetic and Non-Diabetic Individuals by Polyacrylamide Gel Electrophoresis | |
| TR200003184T2 (tr) | ''İnsülin benzeri büyüme faktörünü bağlayan proteinin selektif klivajını yapabilen yeni serin proteazı'' | |
| TAKAGI et al. | Studies on human α1-microglobulin | |
| Yonemasu et al. | C1q, a collagen-like complement subcomponent, in dermatosparactic cattle: its extracellular modification is not affected by lack of procollagen N-terminal proteinase (pN-proteinase) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: ASSIM SENDO, DE ACORDO COM O ART. 37, OPINO PELO INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE A REQUERENTE NAO CUMPRIU AS EXIGENCIAS, DE FORMA A SANAR AS IRREGULARIDADES APONTADAS E EXUSTIVAMENTE DISCUTIDAS PELOS PARECERES TECNICOS ANTERIORES. DESTA FORMA, O PRESENTE PEDIDO NAO E CONSIDERAVEL PATENTEAVEL DE ACORDO COM O ART. 10/IX, EM COMBINACAO COM O ART. 18/III DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: ARQUIVAMENTO DEFINITIVO |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07K 14/575; A23K 1/165; A61K 38/22. Ipc: C07K 14/47 (2006.01), A23K 20/147 (2016.01), C07K Ipc: C07K 14/47 (2006.01), A23K 20/147 (2016.01), C07K |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2295 DE 30/12/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A,15A,16A,17A,18A,19A,20A,21A,22A,23A E 24A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2611 DE 19/01/2021. |